A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

NCT05989828 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Pending Protocol Amendment Approval

Conditions

Triple Negative Breast Cancer

Interventions

BIOLOGICAL: Aldesleukin
BIOLOGICAL: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Cyclophosphamide
PROCEDURE: Echocardiography
DRUG: Fludarabine
PROCEDURE: Leukapheresis
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Mammogram
PROCEDURE: Multigated Acquisition Scan
PROCEDURE: Ultrasound Imaging

Sponsor

University of Southern California

Collaborators

[object Object]